Biggest News Aggregation in the World
📰 Meter Walk Test News

Meter Walk Test News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Meter Walk Test. Real-time updates on events, politics, business and more.

PHARNEXT: After 6 years of total trial time, data from the open-label PLEO-CMT-FU trial are consistent with a long-term benefit of PXT3003 in Charcot-Marie-Tooth Disease Type 1A (CMT1A)

New data from the ongoing Open-Label Phase III Extension Study of PXT3003, the PLEO-CMT-FU trial, are consistent with a good safety profile and long-term treatment effect of PXT3003 measured on
Baden Wüberg United States France General Gewinn Nur Fabreguettes Leib Shahram Attarian

PHARNEXT: Pharnext unveils the latest progress of the PREMIER trial, pivotal Phase III clinical trial of PXT3003 in Charcot-Marie-Tooth disease type 1A

PARIS, France, February 2nd, 2023, 08:30 am CET - Pharnext SA (FR001400BV89 - ALPHA) (the "Company"), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative
United States France General Baden Wüberg Deborah Schwarz Mary Jane Elliott Fabreguettes Leib

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science